Shots:

• The acquisition expands Novartis’ ophthalmology portfolio with the addition of Arctos’ pre-clinical optogenetics-based AAV gene therapy program and its technology
• The acquisition marks the Novartis commitment to identify optogenetics-based therapies for the treatment of patients with vision loss
• Arctos has developed its technology to treat IRDs and other diseases that involve photoreceptor loss- such as AMD. Arctos’ optogene is delivered to specific retinal cells using gene therapy to convert targeted cells into replacement photoreceptor-like cells

  Ref: Novartis | Image: Novartis